Predictors of outcome for EGFR-mutant non-small-cell lung cancer treated with first-line tyrosine kinase inhibitors

ISSN： 1758-1966

Source： Lung Cancer Management, Vol.2, Iss.2, 2013-04, pp. : 89-92

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer

By Kao Hsiang-Fong Lin Chia-Chi Yang James Chih-Hsin

Future Oncology, Vol. 9, Iss. 7, 2013-07 ,pp. : 991-1003

Future Medicine

Access to resources Recommend Favorite

Erlotinib in the first-line treatment of non-small-cell lung cancer

By D'Arcangelo Manolo Cappuzzo Federico

Expert Review of Anticancer Therapy, Vol. 13, Iss. 5, 2013-05 ,pp. : 523-533

Informa Healthcare

Access to resources Recommend Favorite

Usefulness of plasma HGF level for monitoring acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer

Oncology Reports, Vol. 33, Iss. 1, 2015-01 ,pp. : 391-396

Spandidos Publications

Access to resources Recommend Favorite

Is EGF receptor–tyrosine kinase inhibitor therapy in non-small-cell lung cancer patients with EGFR mutations the best option?

By Hayashi Hidetoshi Nakagawa Kazuhiko

Lung Cancer Management, Vol. 2, Iss. 6, 2013-12 ,pp. : 441-443

Future Medicine

Access to resources Recommend Favorite

EGFR–tyrosine kinase mutation testing methods in non-small-cell lung cancer: new diagnostic guidance is NICE

By Wallace Andrew

Lung Cancer Management, Vol. 2, Iss. 6, 2013-12 ,pp. : 449-451

Future Medicine

Access to resources Recommend Favorite